ArticleRisk management and healthcare policy2026
Safety of Mini-Midline Catheters for Intravenous Antimicrobial Therapy Not Exceeding 14 Days: Treatment Completion Rate and Re-Catheterization Needs.
Article in Risk management and healthcare policy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate whether ultrasound-guided mini-midline catheter use (8-15 cm) is associated with treatment completion and safety outcomes compared with short peripheral catheters (<8 cm) for intravenous antimicrobial therapy lasting no more than 14 days, while additionally characterizing device specifications, peripheral drug compatibility, and cumulative vascular-access burden. Methods: This single-center retrospective comparative cohort study included 134 hospitalized adults (55 mini-midline, 79 short PIVC) receiving planned intravenous antimicrobial therapy for 5-14 days. The primary endpoint was treatment completion through the index device. Secondary outcomes included catheter-related complications, re-catheterization, cumulative catheter burden, inflammatory markers, and descriptively summarized dwell time among devices with documented insertion and removal timestamps. Results: Treatment completion was 46/51 (90.2%) for mini-midlines and 79/79 (100.0%) for short PIVCs (unadjusted p=0.005; absolute RD -9.8%; Holm-adjusted p=0.015). Among devices with documented timestamps, median dwell time was 310.0 hours (12.9 days) for mini-midlines and 71.5 hours (3.0 days) for short PIVCs. Complication rates were low, with 3/55 mini-midline patients experiencing 5 catheter-related events and 0/79 short-PIVC patients experiencing catheter-related events. No bloodstream infection or symptomatic thrombosis occurred in either group. Mini-midline patients required fewer total PIVCs per treatment episode, while cumulative insertion attempts were 61 and 85 in the mini-midline and short-PIVC groups, respectively. Diabetes mellitus and ≥2 puncture attempts were associated with treatment non-completion in the mini-midline group. Conclusion: Ultrasound-guided mini-midlines were associated with acceptable safety, longer observed peripheral dwell time, and reduced overall PIVC burden in selected hospitalized patients receiving up to 14 days of peripherally compatible intravenous antimicrobial therapy. Mini-midlines should be considered a complementary vascular-access strategy rather than a universal replacement for short PIVCs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.